---
title: Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult
  People with Cystic Fibrosis
date: '2024-10-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39452571/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241025210316&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Many pwCF under ETI therapy have Cmax values for elexacaftor
  and ivacaftor above the recommended range, even on reduced doses or before the tmax
  was reached. This highlights the value of a TDM program. Further pharmacokinetic
  studies are ...'
disable_comments: true
---
CONCLUSIONS: Many pwCF under ETI therapy have Cmax values for elexacaftor and ivacaftor above the recommended range, even on reduced doses or before the tmax was reached. This highlights the value of a TDM program. Further pharmacokinetic studies are ...